Nuzenio

Insilico

Insilico news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 12 latest news signals 9 publisher sources 100/100 entity strength

Latest news

How Insilico Medicine Is Using AI To Reinvent Drug Discovery - ForbesForbes · Fri, 07 Aug 2026 06:07:08 GMTInSilico Medicine Cayman TopCo (3696.HK) stock price, news, quote and history - uk.finance.yahoo.comuk.finance.yahoo.com · Fri, 07 Aug 2026 02:43:25 GMTInsilico Medicine Nominates ISM9077, Potential First-in-class Target Y Inhibitor, as Preclinical Candidate (PCC) for Ocular Diseases, Inflammatory Disorders and Aging - Insilico MedicineInsilico Medicine · Thu, 06 Aug 2026 09:47:23 GMTInsilico Medicine secures China NMPA IND clearance for AI-designed NLRP3 inhibitor ISM8969/HT-001 in Parkinson's - DealroomDealroom · Wed, 05 Aug 2026 07:13:43 GMTInsilico Medicine highlights AI-powered biological target discovery for rare sinonasal cancer - News-MedicalNews-Medical · Tue, 04 Aug 2026 16:02:00 GMTInsilico's AI-designed TEAD inhibitor secures FDA fast track for mesothelioma - AllSciAllSci · Fri, 31 Jul 2026 12:34:50 GMTInsilico Medicine launches AI drug discovery benchmarking platform - Drug Target ReviewDrug Target Review · Fri, 31 Jul 2026 07:00:00 GMTWeely Conference: Insilico Medicine at Ai4 2026: Dr. Alex Zhavoronkov to deliver two keynote sessions on AI drug discovery and anti-aging - EurekAlert!EurekAlert! · Fri, 31 Jul 2026 02:43:53 GMT

Timeline

Fri, 07 Aug 2026 06:07:08 GMTHow Insilico Medicine Is Using AI To Reinvent Drug Discovery - Forbes
Fri, 07 Aug 2026 02:43:25 GMTInSilico Medicine Cayman TopCo (3696.HK) stock price, news, quote and history - uk.finance.yahoo.com
Thu, 06 Aug 2026 09:47:23 GMTInsilico Medicine Nominates ISM9077, Potential First-in-class Target Y Inhibitor, as Preclinical Candidate (PCC) for Ocular Diseases, Inflammatory Disorders and Aging - Insilico Medicine
Wed, 05 Aug 2026 07:13:43 GMTInsilico Medicine secures China NMPA IND clearance for AI-designed NLRP3 inhibitor ISM8969/HT-001 in Parkinson's - Dealroom
Tue, 04 Aug 2026 16:02:00 GMTInsilico Medicine highlights AI-powered biological target discovery for rare sinonasal cancer - News-Medical
Fri, 31 Jul 2026 12:34:50 GMTInsilico's AI-designed TEAD inhibitor secures FDA fast track for mesothelioma - AllSci

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Insilico.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

9 distinct publisher/source names are currently connected to this entity page.